Antifungal F2G Raises $60m, Sees Harmonized Route To Market
Executive Summary
UK-based antifungal company F2G has raised $60m as it prepares a pivotal trial of its lead drug candidate for the treatment of invasive fungal infections. With both oral and IV formulations of its lead candidate and a harmonized regulatory pathway agreed with the US FDA and EMA, CEO Ian Nicholson believes a 2019 filing is achievable.
You may also be interested in...
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Antifungal firm F2G attracts Novartis despite Neutec flop
The Manchester, UK-based antifungal drug discovery firm F2G has secured a $30 million financing round to advance its early-stage pipeline into the clinic. The company hopes to begin Phase I trials next year of a drug candidate to treat Aspergillus infections from its F3 series, a group of small-molecule compounds based on novel chemistry and a novel target.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.